CAS 1362850-20-1

Seletalisib

CAS : 1362850-20-1

Formule : C₂₃H₁₄ClF₃N₆O

Degré de pureté : 99%

Couleur et forme : Solid

Masse moléculaire : 482.8451

Ref: IN-DA01EOAJ

Seletalisib

CAS : 1362850-20-1

Seletalisib

Degré de pureté : ≥95%

Masse moléculaire : 482.85g/mol

Ref: 54-BUP04946

(R)-3-(8-Chloro-3-(2,2,2-Trifluoro-1-(Pyrido[3,2-D]Pyrimidin-4-Ylamino)Ethyl)Quinolin-2-Yl)Pyridine 1-Oxide

CAS : 1362850-20-1

(R)-3-(8-Chloro-3-(2,2,2-Trifluoro-1-(Pyrido[3,2-D]Pyrimidin-4-Ylamino)Ethyl)Quinolin-2-Yl)Pyridine 1-Oxide

Degré de pureté : 98+%

Masse moléculaire : 482.85g/mol

Ref: 54-PC108594

Seletalisib

CAS : 1362850-20-1

Seletalisib (UCB5857) (UCB5857) is a potent and specific PI3Kδ inhibitor (IC50: 12 nM).

Formule : C₂₃H₁₄ClF₃N₆O

Degré de pureté : 99.81%

Couleur et forme : Solid

Masse moléculaire : 482.85

Ref: TM-TQ0044

Seletalisib (UCB-5857)

CAS : 1362850-20-1

Seletalisib is a novel, potent, and selective inhibitor of the lipid kinase activity. It blocks protein synthesis by binding to the ribosomal protein S6 kinase-1 (RSK1) which is involved in regulating cell proliferation and differentiation. Seletalisib has been shown to be effective in clinical studies for treatment of autoimmune diseases such as systemic lupus erythematosus (SLE). This drug also has pharmacokinetic properties that are suitable for hepatic impairment. Seletalisib also inhibits the production of chemokines, which are inflammatory cytokines that induce chemotaxis of leukocytes and promote inflammation.

Formule : C₂₃H₁₄ClF₃N₆O

Degré de pureté : Min. 95%

Masse moléculaire : 482.85 g/mol

Ref: 3D-MEC85020